The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2022 | Tackling synchronous oligometastases
Alan D. L. Sihoe, MBBChir, FRCSEd, FCSHK, FHKAM, The University of Hong Kong, Pokfulam, Hong Kong, discusses a session taking place at the European Lung Cancer Congress (ELCC) 2022 on how to tackle synchronous oligometastases. Speakers discuss how to treat patients with stage IV synchronous oligometastatic lung cancer, including the role of surgery and radiotherapy, as well as maintenance therapy for patients with stage IV synchronous oligometastatic lung cancer. This interview took place during the virtual European Lung Cancer Congress 2022.
